Source: United States Department of Justice 2
The Justice Department’s Antitrust Division announced today that it has completed its review of a proposed joint patent licensing pool known as the University Technology Licensing Program (UTLP). UTLP is a proposal by participating universities to offer licenses to their physical science patents relating to specified emerging technologies.
Source: United States Department of Justice 2
On Jan. 13, 2021, President Donald J. Trump signed into law the Competitive Health Insurance Reform Act of 2020 (the “Act”), which limits the antitrust exemption available to health insurance companies under the McCarran-Ferguson Act. The Act, sponsored by Rep. Peter DeFazio, passed the House of Representatives on Sept. 21, 2020 and passed the Senate on Dec. 22, 2020.
Source: United States Department of Justice 2
A federal grand jury returned a two-count indictment charging Surgical Care Affiliates LLC and its related entity (collectively SCA), which own and operate outpatient medical care centers across the country, for agreeing with competitors not to solicit senior-level employees, the Department of Justice announced today. These are the Antitrust Division’s first charges in this ongoing investigation into employee allocation agreements.
Source: United States Department of Justice 2
The Department of Justice announced today that it has completed its investigation into whether Georgetown Day School, Holton-Arms School, Landon School, Maret School, National Cathedral School, The Potomac School, St. Albans School, and Sidwell Friends School (jointly, “the Schools”) collectively agreed to stop offering Advanced Placement (AP) courses by 2022 in violation of the Sherman Act. The Schools announced in June 2018 that they would eliminate AP courses from their curricula by 2022.
Source: United States Department of Justice 2
The Department of Justice announced today that it has no intention to challenge proposed efforts by Baxalta US Inc., Emergent BioSolutions Inc., Grifols Therapeutics LLC, and CSL Plasma Inc. (together, the “Requesting Parties”) to assist the Biomedical Advanced Research and Development Authority (BARDA) in designing quality standards for collecting COVID-19 convalescent plasma.